Market revenue in 2022 | USD 4,832.2 million |
Market revenue in 2030 | USD 8,431.1 million |
Growth rate | 7.2% (CAGR from 2022 to 2030) |
Largest segment | Estrogen and progesterone replacement therapy |
Fastest growing segment | Parathyroid Hormone replacement |
Historical data covered | 2018 - 2021 |
Base year for estimation | 2022 |
Forecast period covered | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Estrogen and Progesterone Replacement Therapy, HGH replacement therapy, Thryoid hormone replacement therapy, Testosterone Replacement Therapy, Parathyroid Hormone replacement |
Key market players worldwide | Eli Lilly and Co, Bayer AG, Hisamitsu Pharmaceutical Co Inc, Pfizer Inc, Merck & Co Inc, Viatris Inc, Novo Nordisk A/S ADR, AbbVie Inc, Roche Holding AG ADR, Ascend Wellness Holdings Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hormone replacement therapy market will help companies and investors design strategic landscapes.
Estrogen and progesterone replacement therapy was the largest segment with a revenue share of 53.41% in 2022. Horizon Databook has segmented the Asia Pacific hormone replacement therapy market based on estrogen and progesterone replacement therapy, hgh replacement therapy, thryoid hormone replacement therapy, testosterone replacement therapy, parathyroid hormone replacement covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific is an emerging market with economies such as Japan, China, India, Australia, and South Korea at the forefront. Growing incidence of diseases caused by hormonal imbalances, such as menopause, hypothyroidism, growth hormone deficiencies, and hypoparathyroidism, is projected to drive the market growth.
As per Journal of the North American Menopause Society (May 2022), the prevalence of vasomotor symptoms associated with menopause has been reported to range from 43% to 83% in women in East Asian countries. Thus, growing number of women reaching menopause is expected to drive the demand for hormone replacement therapy in the region.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific hormone replacement therapy market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific hormone replacement therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account